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CHAPTER I
INTRODUCTION
Coronary heart disease (CHD) is the number one cause of death in men and
women in all developed countries (Bales, 2000). Premenopausal women have a lower
incidence of heart disease than their male counterparts, however, following menopause
the CHD rate for women is virtually the same as men (AHA, 2002).
Ovarian hormone deficiency brings about physiological changes that are
concurrent with an increased risk for heart disease; most predominant is the undesirable
alteration in serum lipids (Nathan & Chaudhuri, 1997). Elevated lipoproteins in the blood
have been strongly correlated with an increased risk for CHD (Kannel et aI., 1971).
Observational studies have shown that the use of exogenous estrogen in the fann
of estrogen replacement therapy (ERT) can reduce and sometimes prevent these
unfavorable cardiovascular changes brought about by menopause. Clinical studies have
also supported the role of ERT in correcting dyslipidemias, but the long-term benefits of
ERT still need to be investigated. In fact, recent clinical studies have failed to show long-
term cardioprotective benefits ofERT (Hulley et aI., 1998). Also, unopposed estrogen use
is associated with an increased risk for uterine and breast cancer, and for thrombosis
(Tsang et aI., 2000). The addition of progesterone to the hormone replacement therapy
(HRT) lowers the risk of hormone-induced endometrial hyperplasia but it may also
reduce the cardiovascular benefits of the exogenous estrogen (Tsang et aI., 2000).
Along with the undesirable side effects and risks of ERT, many women are
unwilling to take medications on a long-term basis or unable to afford it (Keating et aI.,
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1999; Rabin et aI., 1999). Only a maximum of30% of postmenopausal women use ERT
(Lobo, 1995) and women often discontinue its use after only one year (Barrett-Connor et
aI., 2000).
Researchers are attempting to develop safer alternatives to ERT. Selective
estrogen receptor modulators (SERMs) may be a viable option. SERMs are a group of
medications that possess tissue specific estrogenic or antiestrogenic effects (Grese &
Dodge, 1998; Weryha et aI., 1999; Cosman & Lindsay, 1999). These compounds were
first developed for the treatment of estrogen receptor positive breast cancer and were
found to not only function as estrogen antagonists in breast but, at the same time, as
estrogen agonists in bone and cardiovascular tissue (Cosman & Lindsay, 1999). These
first generation SERMs, like tamoxifen, were found to increase the risk of some uterine
diseases but second generation SERMs, like raloxifen, do not cause uterine stimulation
(Cosman & Lindsay, 1999; Grese & Dodge, 1998). Pharmaceutical research is being
conducted to develop SERMs that could replace traditional HRT by relieving menopausal
symptoms such as hot flashes, heart disease, and osteoporosis, without the side effects of
estrogen (Grese & Dodge, 1998; Weryha et aI., 1999; Cosman & Lindsay, 1999).
Recent reports indicate that phytoestrogens exert their effects in a similar manner
as SERMs (Brzezinski & Debi, 1999). Phytoestrogens are non-steroidal compounds
found in a variety of plants. Food sources rich in phytoestrogens may provide women
with a practical and safe alternative for the alleviation of postmenopausal increases in
cholesterol levels.
Diet has been shown to influence serum cholesterol levels and heart disease
outcomes. Phytoestrogens are found in many foods including legumes, grains, sprouts,
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fruits, and vegetables (Setchell & Cassidy, 1999). The three major classes of
phytoestrogens are isoflavones, lignans, and coumestans (Thompson, 1998). Flaxseed is
the richest source of lignans (Thompson, 1998), a group of polyphenolic compounds with
antioxidant activity. Flaxseed is believed to have many health benefits including:
protection against certain fOnTIS of cancer (Thompson, 1998); reduction in cardiovascular
disease risk (Arjmandi et aI., 1998; Cunnane et aI., 1995; Prasad et aI., 1998); and, partly
due to its anti-inflammatory properties, impedance in the progression of kidney disease
(Clark et aI., 1995; Ogborn et aI., 1999, Velasquez & Bhathena, 2001).
The hypothesis of this study is that the daily consumption of flaxseed by
postmenopausal women, not on HRT, improves their lipid profiles as well as reduces
serum levels of c-reactive protein (CRP), a general marker of inflammation. To test this
hypothesis we have three specific aims:
Specific aim 1: To detennine whether daily consumption of 40 grams ground
flaxseed, by postmenopausal women, reduces total cholesterol (TC), low-density
lipoprotein (LDL) -cholesterol, and triglyceride (TG) levels.
Specific aim 2: To evaluate whether daily consumption of 40 grams ground
flaxseed, by postmenopausal women, maintains/increases high-density lipoprotein (HDL)
cholesterol and apolipoprotein A (apo A) levels, both of which have favorable effects on
lipid profiles.
Specific aim 3: To examine whether daily consumption of 40 grams ground
flaxseed, by postmenopausal women, decreases serum levels of CRP.
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CHAPTER II
REVIEW OF LITERATURE
PREVALENCE OF HEART DISEASE IN THE UNITED STATES
Coronary heart disease (CHD) is the leading cause of mortality in the United
States for men and women as well as the leading cause of death in all other industrialized
countries (AHA, 2002). About 12.4 million Americans have some form of CHD (AHA,
2002).
Economically, CHD has a severe impact. In the United States alone the direct
costs of health care as well as indirect costs of loss in productivity as a result of CHD are
currently estimated to be around $100.8 billion annually (AHA, 2002).
CHD mortality rates are 50.8% and 49.2% for men and women respectively but it
is a common misconception that women have a much lower risk for developing heart
disease than men, due to the fact that heart disease manifests in women 10 years later
than in men. In the Framingham study, 2873 women were monitored for 24 years and
during that time no premenopausal women experienced a myocardial infarction or died
from coronary heart disease (Gordon et aI., 1978). Researchers found that the incidence
of CHD in postmenopausal women, between the ages of 45 to 54 years, was twice that of
premenopausal women of the same age group (Gordon et aI., 1978). Subsequent human
trials have resulted in consistent findings (Nathan & Chaudhuri, 1997). These gender
differences have been seen in laboratory animals as well (Nathan & Chaudhuri, 1997). It
was this increase in CHD in women corresponding to the cessation of ovarian honnone
production that led researchers to investigate the cardioprotective effects of estrogen.
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RISK FACTORS FOR CORONARY HEART DISEASE FOLLOWING MENOPAUSE
There are many risk factors for heart disease: age, family history of premature
CHD, elevated TC, elevated LDL-cholesterol, low levels ofHDL-cholesterol, high serum
TG, elevated CRP, hypertension, current smoking, and obesity are just a few examples
(Davidson & Maki, 1998). Women potentially have the additional risk factor of
postmenopausal status without ERT.
This classification is due to the epidemiological evidence showing an increase in
the incidence of CHD following menopause. Menopause brings about physiological
changes that can negatively affect the cardiovascular system. Studies have shown that
following menopause, there is a dramatic increase in blood pressure (Staessen et aI.,
2001). The increase in blood pressure is believed to be due to changes in vascular tone
and/or changes in endothelium-derived chemicals that influence dilation and constriction
of blood vessels (Koh et aI., 2001; Brooks et aI., 1997). One study conducted by Noto et
ai. (2000) involving 24-hour blood pressure monitoring revealed periodic increases in
blood pressure ofpostmenopausal women throughout the 24-hour period. These increases
were more pronounced during sleep and in those with surgical menopause. An increase in
intra-abdominal fat is also seen which can put women at an increased risk for insulin
resistance and CHD (Tchemof & Poehlman, 2000; Toth et aI., 2000).
More extensively studied is the change in serum lipid levels that coincide with
cessation of ovarian functio11. The Framingham Study revealed that following surgical or
natural menopause, women experienced a significant rise in total cholesterol (Hjortland et
aI., 1976). Cholesterol levels for this report were from examinations performed two years
apart, one prior to menopause and one after, therefore this increase was considered to be
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seen within a short period of time. Since the Framingham results, studies have
consistently shown an increase in TC and LDL-cholesterol concentrations following
menopause (Pansini et aI., 1993; Kim et aI., 2000; Pasquali et aI., 1997; Fukami et aI.,
1995; Stevenson et aI., 1993; de Aloysoio et aI., 1999). However, the effect of menopause
on HDL-cholesterol levels remains contentious. Studies have shown that, with. the onset
of menopause, HDL-cholesterol concentrations decrease (Tsang et aI., 2000) while other
studies have shown an increase in HDL-cholesterol concentrations (Kim et aI., 2000;
Pansini et aI., 1993). HDL-cholesterol levels have also been shown to remain constant
during the transition from premenopausal to postmenopausal (Gardner et aI., 2000;
Fukami et aI., 1995; Pasquali et aI., 1997; de Aloysio et aI., 1999). Study findings on TG
levels following menopause are also varied. While some studies have found no change in
TG levels (Gardner et aI., 2000; Fukami et aI., 1995; Pasquali et aI., 1997; de Aloysio et
aI., 1999), others have reported increases (Kim et aI., 2000; Tsang et aI., 2000).
Another risk factor for heart disease is elevated CRP concentrations. CRP is
produced in the liver, along with other acute phase proteins, following cytokine
stimulation (Lagrand et aI., 1999). CRP is a sensitive marker of inflammation due to
bacterial infection, trauma, or tissue damage (Koenig et aI., 1999). Serum levels of CRP
respond rapidly to inflammation as well as its resolution (Du Clos et aI., 2000). CRP is
believed to function as either a surveillance molecule (Du Clos, 2000) or a host defense
(Volanakis, 2001) to protect against pathogens and to remove necrotic cells. Normally,
CRP levels are less than 8 mg/dL. Elevated CRP levels in apparently healthy individuals
are associated with increased risk of cardiovascular' events and increases following a
myocardial infarction correlate with severity and outcome (Lagrand et aI., 1999; Ridker
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et aI., 2000). Therefore, an elevated CRP levels with or without other CHD risk factors is
cause for alann and modifications of lifestyle.
PREVENTION AND TREATMENT OF CORONARY HEART DISEASE IN WOMEN
LIFESTYLE MODIFICATION
The first step in treating hypercholesterolemia, depending on the degree of
severity and the existence of concomitant CHD risks, is lifestyle changes. Changes may
include smoking cessation, weight reduction, increased physical activity and dietary
modification.
The National Cholesterol Education Program (NCEP) and the American Heart
Association (AHA) recommendations include; a diet high in plant foods, choosing fat-
free or low fat dairy and meats, and consuming two servings of fish per week (AHA
Scientific Position). These guidelines are specified in the AHA's Step I and Step II diets.
The AHA no longer uses the designations "Step I" and "Step II" but the dietary
guidelines remain the same. The revised guidelines focus on an overall healthy diet and
not on specific numbers and percentages. On the Step I diet, 30% or less of the total
calorie intake comes from fat. Of that 30%, less than 7% is to come from saturated fat, up
to 10% from polyunsaturated fat and 20% or less from monounsaturated fat. The Step I
diet also limits the intake of cholesterol to less than 300 mg/day. The Step II diet is used
if CHD is already present or if lipid goals are not met after following the Step I diet. It
further restricts intakes of cholesterol and saturated fat.
The Step I and Step II diets can reduce LDL-cholesterollevels as much as 9% and
20%, respectively (Stone et aI., 1996; Bunyard et aI., 2002). It has been shown repeatedly
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that reduction of dietary cholesterol and saturated fat will reduce the risk of CHD
(Gylling & Miettinen, 2001). Other components of a cholesterol lowering diet are soluble
fibers, monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs).
It has been well documented that diets high in fiber reduce the risk of heart
disease. Clinical studies have shown that fiber reduces LDL-cholesterol by an average of
9% (Fernandez, 2001). Fiber has also been shown to increase HDL-cholesterol in rats
(Bagger et aI., 1996). A prospective cohort study of participants from the first National
Health and Nutrition Examination Survey (NHANES I) data showed that a diet high in
soluble fiber, in the form of legumes, is inversely related to CHD risk (Bazzano et aI.,
2001). One study revealed a significantly greater decrease in TC and LDL-cholesterol in
a hypocaloric diet that included oats compared to a hypocaloric control diet (Saltzman et
aI., 2001).
The AHA's recommendation to substitute a portion of dietary saturated fat with
MUFAs such as canola oil and olive oil, and PUFAs such as soybean oil, com oil, fish
oil, and flaxseed oil are based on studies showing improved lipid profiles as a result of
these dietary changes. A high-fat (34% of calories from fat) MUFA diet reduced TC by
10%, LDL-cholesterol by 14%, and TG by 13% (Kris-Etherton et aI., 1999). Gustafsson
et ai. compared the lipid lowering effect of MUFAs in the form of canola oil with PUFAs
in the fonn of sunflower oil and found similar reductions in total-, LDL-, and HDL-
cholesterol (Gustafsson et aI., 1994). Triglyceride levels increased significantly in both
groups with a much greater increase in the PUFA group.
The AHA's recommendation to consume fish twice a week is partly the result of
studies associating high fish consumption with a low risk of CHD. Marine oils contain u-
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linolenic acid (ALA), an essential omega-3 fatty acid, and its metabolites eicospentaenoic
acid (EPA) and docosahexaenoic acid (DHA) (Mantzioris et aI., 2000). At high doses
omega-3 fatty acids from fish oils lower cholesterol and triglycerides and have anti-
thrombotic and anti-inflammatory activity (Simopoulos et aI., 1991). Consumption of
flaxseed oil, another rich source of ALA, results in increases in tissue EPA but not DHA
while consunlption of fish oil results in elevated tissue concentrations of both EPA and
DHA (Mantzioris et aI., 2000). However, clinical studies using ALA in the form of
flaxseed oil have shown that flaxseed oil may also protect against cardiovascular disease.
Study results have also indicated increased arterial compliance or elasticity (Nestel et aI.,
1997) and reduced platelet aggregation (Allman et aI., 1995).
Many different food items labeled functional foods are under investigation for
their lipid lowering effects; soy foods, flaxseed, oatmeal, garlic, and grapes are just a few
examples. In 1999 the Food and Drug Administration (FDA) approved the health claim
that the daily consumption of 25 grams of soy protein reduces the risk of heart disease
(DHHS, 1999). The group petitioning the FDA presented more than 40 studies verifying
the health benefit of soy foods. The FDA agreed that soy protein reduces TC and LDL-
cholesterol but the component that is behind this lipid lowering effect has yet to be
determined; it could be isoflavones, saponins, phytic acid, trypsin inhibitors, fiber, or
globulins present in soy protein (Hasler et aI., 2000).
CHOLESTEROL LOWERING DRUGS
Diet modification and weight loss are quite effective in lowering LDL-cholesterol
and TC, and exercise can increase HDL-cholesterol levels but if these lifestyle changes
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are not possible or are not sufficient, medications will often be prescribed. There are a
variety of drugs with different mechanisms of action. The type of drug chosen depends
on the nature of the dyslipidemia. Statin or other 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitor drugs inhibit HMG-CoA reductase, the rate-limiting
enzyme in cholesterol synthesis. Statin is the most potent of the cholesterol lowering
drugs but its expense does limit its use. These drugs lower LDL-cholesterol and TG
concentrations and can raise HDL-cholesterol concentrations in some individuals. Niacin
increases HDL-cholesterol and decreases LDL-cholesterol and TG levels but can cause
itching and flushed skin due to the release of histamine and prostaglandins. However,
timed-release niacin reduces these symptoms. Fibric acid derivatives such as gemfibrozil
and fenofibrate have little effect on LDL-cholesterol levels but they do reduce TG and
increase HDL-cholesterol concentrations. Bile acid sequestrants are effective in reducing
LDL-cholesterollevels but may raise TG levels (Kuncl & Nelson, 2000).
HORMONE REPLACEMENT THERAPY
ERT may prevent cardiovascular changes, such as increased serum cholesterol
levels, that lead to CHD. Much of our current knowledge of the cardioprotective effects
of estrogens has been derived from studies involving ERT or HRT. Estrogen therapy has
been shown to improve lipid profiles and through direct action on vascular endothelium
improve blood pressure and slow the buildup of atherosclerotic plaque (Nathan &
Chaudhuri, 1997).
Atherosclerosis is responsible for the majority of CHD related deaths (AHA,
2002). It is an inflammatory condition characterized by the development of plaque on the
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walls of blood vessels. Myocardial infarction or stroke can result when plaque becomes
dislodged fonning a thrombus. The mechanisms behind estrogens ability to slow the
progression of plaque development are not well understood. Although the benefits of
estrogen may affect any stage in the progression, it is the early stages, such as cholesterol
reduction, that have been most extensively studied. It has been estimated that the
improvement of serum lipid levels is responsible for 20% of estrogens benefit (Rosano &
Panina, 1999).
Animal and human studies have repeatedly shown estrogens ability to reduce
serum LDL-cholesterol levels and increase HDL-cholesterol levels. ERT also increases
circulating TG concentrations in the form of very low-density lipoprotein (VLDL)
particles. Although VLDL particles are generally considered to be atherosclerotic, those
produced following the use of exogenous estrogens are believed to be less likely to enter
the arterial wall because they are buoyant and cholesterol-poor (Knopp et aI., 1996).
Estrogen increases all major pathways for cholesterol transport (Knopp et aI.,
1996). Upregulation of LDL receptors allows more LDL particles to be taken up by the
liver and used for the production of steroids or bile salts. HDL-cholesterol production is
increased, as is the production of apo A. There is also a decrease in hepatic lipase
activity, this causes LDL-cholesterol particles to accumulate a higher percentage of
triglycerides resulting in a larger and more buoyant molecule that is less likely to become
trapped in the arterial wall. Hepatic lipase also increases the uptake of HDL-cholesterol;
therefore, by decreasing the activity of hepatic lipase with estrogen more HDL-
cholesterol remains in circulation (Knopp et aI., 1996).
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Several observational studies have shown that ERT is associated with a decrease
in all cause mortality rates by 30-50% (Greendale et aI., 1999). Previously, the majority
of the research conducted on ERT and CHD has been observational and animal studies.
In the last five years however, large clinical studies have been conducted to investigate
the effects ofERT on CHD risk factors and CHD events in postmenopausal women with
and without heart disease. Some of the findings have been surprising and all together
inconclusive. The Heart and EstrogenJProgestin Replacement Study (HERS) found no
advantage to HRT in women with heart disease. The study included 2763
postmenopausal women less than 80 years of age with CHD. The intervention consisted
of either 0.625mg conjugated equine estrogen plus 2.5mg medroxyprogesterone acetate
or placebo. After 4 years, no differences were seen between the two groups and during
the first year of the study there was actually a greater incidence of CHD-related events in
the treatment group (Rulley et aI., 1998). This increased incidence of CRD may have
been due to the prothrombotic or proinflammatory effect of exogenous estrogen
(Herrington & Klein, 2001). In the Estrogen Replacement and Atherosclerosis (ERA)
study, 309 postmenopausal women with coronary artery atherosclerosis were randomly
assigned to one of three treatment groups; unopposed conjugated equine estrogen,
estrogen plus medroxyprogesterone, or placebo. After three years of treatment, no
differences were seen between the three groups in the progression of atherosclerosis
(Herrington & Klein, 2001). Th.e only study to look at the effect of estrogen in primary
prevention of CHD was the Estrogen in the Prevention of Atherosclerosis Trial (EPAT).
This study was a two-year placebo controlled study of 199 postmenopausal women. The
subjects had elevated LDL-cholesterol levels but no evidence of eHD. Women with
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diabetes mellitus or a history of smoking were excluded from the study. Those with LDL-
cholesterol levels greater than 160 mg/dL were given lipid lowering medications. In this
study estrogen was beneficial, the subjects that received unopposed estrogen had a lower
rate of progression of atherosclerosis compared to those that received the placebo as
measured by intima-media thickness of the right common carotid artery (Hodis et aI.,
2001; Herrington & Klein, 2001).
It has been reported that less than 30% of postmenopausal women in the United
States receive HRT (Lobo, 1995) and out of these women most discontinue use after one
year (Barrett-Connor et aI., 2000). Most women begin taking ERT for relief of hot flashes
and stop taking them when the potential for hot flashes has passed. Women may also quit
taking ERT for financial reasons (Barrett-Connor et aI., 2000). Resistance to HRT use is,
in part, due to the risk of side effects such as irregular bleeding and the increased risk for
the development of certain cancers and thrombosis (Lobo, 1995). These undesirable
effects of estrogen therapy are a result of its non-specific estrogenic effect.
SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs)
Selective estrogen receptor modulators (SERMs) are nonsteroidal compounds that
produce tissue-specific estrogenic or antiestrogenic response (Weryha et aI., 1999).
SERMs were initially designed as antiestrogens for the treatment of estrogen receptor
positive breast cancer. Following the widespread use oftamoxifene, the first antiestrogen,
it was discovered that it had an estrogen-like affect on bone metabolism (Weryha et aI.,
1999). Tamoxifene was also found to cause endometrial hyperplasia, as does estrogen
replacement therapy (Weryha et aI., 1999). The second generation of SERMs, including
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raloxifene, have antiestrogenic affects on breast tissue and estrogenic affects on bone and
the cardiovascular system but do not cause endometrial hyperplasia as tamoxifene or first
generation SERMs have (Grese & Dodge, 1998). The effects of SERMs on the risk
factors of cardiovascular disease vary from the effects seen with HRT. Both reduce TC
and LDL-cholesterol concentrations but SERMs do not cause the rise in TG or HDL-
cholesterol levels that HRT does (Cosman & Lindsay, 1999; Grese & Dodge, 1998).
SERMs also have been shown to reduce fibrinogen levels, another possible risk factor for
heart disease, while HRT does not cause this reduction (Cosman & Lindsay, 1999; Grese
& Dodge, 1998). SERMs may replace HRT for treatment of postmenopausal symptoms
such as hot flashes as well as preventing the chronic diseases associated with estrogen
deficiency such as heart disease and osteoporosis (Brzezinski & Debi, 1999).
PHYTOESTROGENS
Phytoestrogens exert tissue specific estrogenic/antiestrogenic effects as seen with
SERMs (Brzezinski & Debi, 1999). Phytoestrogens are non-steroidal plant compounds
that are structurally and functionally similar to estrogen and SERMs (Brzezinski & Debi,
1999). There are three main classes of phytoestrogens: isoflavones, coumestans, and
lignans (Humfrey, 1998). Isoflavones are most abundant in soybeans, coumestans are
derived from alfalfa sprouts and clover, and lignans are found in a variety of grains and
oilseeds with flaxseed having the highest concentration (Lissin & Cooke, 2000).
Isoflavones were first discovered in 1931 but the hormonal effects were not
realized until the mid-1940's (Setchell, 2000). Urinary metabolites were unintentionally
discovered in human urine in the early 1980's, this sparked the interest in the use of
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phytoestrogens in human nutrition (Setchell, 2000). So far, most of the phytoestrogen
research has been done on the isoflavones found in soybeans (Lissin & Cooke, 2000).
Phytoestrogens are widespread in our food supply, they are found in cereal,
grains, beans, fruits and vegetables. Epidemiological data demonstrates a lower incidence
of chronic diseases such as heart disease and osteoporosis in people consuming diets rich
in phytoestrogens (Lissin & Cooke, 2000). Asian countries that consume a plant-based
diet high in soy foods have lower rates of female CHD mortality, breast cancer mortality,
and lower rates of endometrial cancer (Burke et aI., 2000). There are also fewer reported
menopause-related vasomotor symptoms (Burke et aI., 2000). To further emphasize the
health benefits of the traditional Asian diet, a recent survey of Japanese citizens found a
relationship between the deterioration of the health of the nation and the increasingly
Westernized dietary patterns (Setchell, 1998).
Phytoestrogens exist in plants as glucose conjugates, or glycones, and before the
phytoestrogens can be absorbed the glucose molecule must be removed (Anderson &
Gamer, 1997). Hydrolysis takes place in the jejunum by glucosidases to produce
aglycones (Setchell & Cassidy, 1999). Aglycones are further metabolized by intestinal
bacteria to more estrogenically potent compounds (Setchell & Cassidy, 1999). The
production of bacterial metabolites varies greatly between individuals depending on their
gastrointestinal flora, antibiotic use, and other constituents of the diet (Anderson &
Gamer, 1997; Setchell & Cassidy, 1999).
The aglycones and its bacterial metabolites are absorbed and distributed
throughout the body in the same manner as other fat-soluble molecules and undergo
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enterohepatic circulation (Anderson & Gamer, 1997). Phytoestrogen metabolites are
stored in the liver and adipocytes and excreted in the urine (Anderson & Gamer, 1997).
Phytoestrogens compete with estradiol for binding to estrogen receptors (Grese &
Dodge, 1998) but with higher affinity for estrogen receptor~ (ER~) than for estrogen
receptora (ERa) (Setchell & Cassidy, 1999). ERp are found in tissues such as brain,
thymus, lung, blood vessels, breast, uterus, prostate, bladder, and bone (Setchell &
Cassidy, 1999).
In premenopausal women, consumption of soy foods has caused lengthening of
the menstrual cycle and changes in certain honnone levels (Setchell & Cassidy, 1999). In
postmenopausal women, epidemiological data have suggested that phytoestrogens reduce
the incidence of hot flushes, breast cancer, and osteoporosis (Setchell & Cassidy, 1999).
Clinical trials have had variable results of the effect of phytoestrogens on hot flushes and
maturation index (Setchell & Cassidy, 1999). It has been suggested that the differences in
the outcomes of these clinical studies is due to differences in study design and the
variability in phytoestrogen metabolism in study participants (Setchell & Cassidy, 1999).
Variation in isoflavone content of crops may also playa role in these study outcomes
(Lissin & Cooke, 2000).
LIGNANS
Lignans are a class ofphytoestrogens that are found in a variety of plants but most
abundantly in grains and oily seeds (Thompson, 1998). The most prominent lignans,
enterodiol and enterolactone, are derived from secoisolariciresinol diglycoside (SDG) and
matairesinol, respectively, through the action of colonic bacteria (Thompson, 1998).
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After formation in the colon, lignans are absorbed, undergo enterohepatic circulation, and
are eventually excreted in the urine.
Structural similarities between lignans, as well as other phytoestrogens, and
estrogen led researchers to investigate the possible estrogenic effects of lignans. Many in
vitro studies have demonstrated the hormonal effect of lignans (Thompson, 1998) and it
is believed that these hormonal effects contribute to the cancer preventive effects of
lignans.
The cancer preventive effects could also be due to the antioxidant properties of
lignans (Prasad, 1997b; Kitts et aI., 1999). Free radicals cause DNA damage,which can
potentially allow the proliferation of cancerous cells (Thompson, 1994). Free radical
damage has also been associated with atherosclerosis, diabetes, cataracts, inflammatory
disorders, and aging (Thompson, 1994).
FLAXSEED
Flaxseed is the richest source of the lignan precursor SDG (Thompson, 1998). It
is an edible grain that is of interest due to the health promoting properties of its various
components. Along with a high lignan concentration, flaxseed is a rich source of ALA, an
omega-3 fatty acid. Flaxseed contains an average of 35% of its mass as oil, of which
about 15% is ALA (Prasad, 1999). Flaxseed is also high in soluble fiber, which has
repeatedly been shown to reduce blood cholesterol levels.
The majority of the research into the health benefits of flaxseed has been in the
area of cancer treatment, but other areas of research include polycystic kidney disease
(Ogborn et aI., 1999), lupus nephritis (Ogborn et aI., 1999), arthritis (Nordstrom et aI.,
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1995), hypercholesterolemia (Arjmandi et aI., 1998; Cunnane et aI., 1995),
atherosclerosis (Prasad et aI., 1998), and arterial function (Talom et ai, 1999). Flaxseed's
ability to protect against cancer, particularly of the colon, skin and breast, may be due to
the weak estrogenic/antiestrogenic effects as well as the antioxidant properties of lignans
(Thompson, 1998).
Clinical studies of the estrogenic effect of flaxseed have not been conclusive. For
example, one study conducted by Hutchins et aI. (2001) found that serum concentrations
of 17~-estradioland estrone sulfate were significantly reduced in postmenopausal women
after seven weeks of consuming 5 or 10 grams of ground flaxseed per day. Another study
of premenopausal women found that 10 grams of flaxseed per day did not affect
circulating estrone or estradiol levels (Phipps et aI., 1993).
The effects of flaxseed on cardiovascular health have been more apparent. Animal
studies have shown that flaxseed reduced TG, TC, and LDL-cholesterol in rats receiving
20% of their diet from flaxseed for 90 days (Ratneyake et aI., 1992). A high flaxseed diet
(20%) also improved endothelial vasorelaxation in spontaneously hypertensive rats
(Talom et aI., 1999). Talom et ai. (1999) believe that these findings were due to the ALA
content of the flaxseed since similar results have been seen with fish oils.
At least three studies have shown the positive effects of flaxseed on
atherosclerosis (Prasad, 1997a; Prasad et aI., 1998; Prasad, 1999). All three studies
showed that flaxseed reduced hypercholesterolemic atherosclerosis in rabbits. The first
study (Prasad, 1997a) reported a reduction in atherosclerotic plaque without a reduction
in cholesterol levels. Prasad et ai. (1998) used low ALA flaxseed and found that it
reduced atherosclerotic plaque along with TC and LDL-choiesteroi. Finally, in 1999,
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Prasad demonstrated rabbits fed SDG isolated from flaxseed had reduced atherosclerotic
plaque in addition to lower levels ofTC and LDL-cholesterol.
Flaxseed has also been shown to reduce TC and LDL-cholesterol concentrations
in human subjects. Jenkins et al. (1999) reported that hyperlipidemic subjects (n==29)
consuming partially defatted flaxseed (50 g/day) incorporated into muffins along with a
self-selected AHA Step II diet for 3 weeks had lower serum levels of TC (4.6%), LDL-
cholesterol (7.60/0), apo B (5.4%), and apo A (5.8%). Bierenbaum et ai. (1993) showed
that the incorporation of flaxseed along with 800 IV of vitamin E per day for three
months reduced TC and LDL-cholesterollevels of 15 hyperlipidemic subjects. A double-
blind cross-over study comparing the effects of sunflower seed and flaxseed on serum
cholesterol levels of hyperlipidemic postmenopausal women showed that 38 grams of
flaxseed per day in the fonn of bread products significantly reduced LDL-cholesterol by
14.7% (Arjmandi et aI., 1998). Findings by Cunnane et ai. (1993; 1995) further
corroborate the hypocholesterolemic effect of flaxseed. Both studies found that 50 grams
of flaxseed (traditional and high ALA varieties) significantly lowered TC and LDL-
cholesterol in nonnocholesterolemic young women (mean age-24 years).
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CHAPTER III
MATERIALS AND METHODS
SUBJECT RECRUITMENT
Following approval of the study protocol by the Institutional Review Boards at
Oklahoma State University and the University of Oklahoma Health Sciences Center,
fifty-eight postmenopausal women were recruited from the Oklahoma City area though
radio and newspaper advertisement. The inclusion criteria for the subjects were:
postmenopausal for 1 to 12 years (determined by 1 year of amenorrhea), less than sixty-
five years of age, and not on HRT for at least three months prior to starting the study.
Women were excluded from the study if they were taking any prescribed medications
that would affect lipid or bone metabolism. Women were also excluded if they had any of
the following conditions: cancer, liver disease, thyroid disorder, gastrointestinal
problems, insulin-dependent diabetes mellitus, pelvic inflammatory disease, or
endometrial polyps. After receiving a written and oral explanation of the study protocol,
subjects signed a consent form. A complete medical history was obtained prior to
initiating the treatments. All subjects were given a routine physical and gynecological
examination including a vaginal smear, performed by a gynecologist and evaluated by a
pathologist. The subjects were asked to maintain their usual dietary and physical activity
routines.
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EXPERIMENTAL DESIGN
Upon entry into the study, subjects were randomly assigned to one of two dietary
treatments (n = 29 per treatment) in a double blind comparative control study. In order to
randomly assign subjects, as they entered the study they drew their subject number from
a collection of all possible numbers. The same procedure was followed to assign subjects
to either group A (flaxseed) or group B (wheat). The dietary treatments consisted of 40
grams of either ground whole flaxseed or wheat-based comparative control regimen to be
consumed daily for a period of three months. Both regimens were similar in
macronutrient compositions (Table 1). Study participants were given suggestions for
incorporating the products into their diets. Subjects also received 1,000 mg elemental
calcium plus 400 ill vitamin D supplements to provide some protection against rapid
bone loss. Unused flaxseed or wheat-based regimens, supplements, and a self-recorded
treatment intake log were returned in order for investigators to monitor intake. Treatment
regimens and supplements were provided monthly.
DIETARY ASSESSMENT
Seven-day food frequency questionnaires were administered at baseline and at the
end of the study. The subjects used measuring cups and food portion models while filling
out the food frequency questionnaire in order to estimate serving sizes. Nutrient analysis
was perfonned using food analysis software (Food Processor version 7.4, ESHA
Research, Salem, OR).
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ANTHROPOMETRIC MEASUREMENTS
At baseline standing height, knee height, and weight were obtained as well as
circumferences of the waist, hip, wrist, and upper arm. To estimate body fat percentage
three skin fold measurements were taken at the abdomen, suprailiac crest, and tricep and
those values were used in the following equation:
Percent body fat == 0.41563 (Xl) - 0.00112 (X I)2 + 0.03661 (X2) + 4.03653
where Xl == sum of triceps, abdomen, and suprailiac skinfolds and X 2 == age in years (Lee,
1996).
Measurements were repeated at the end of the study excluding standing height,
knee height and wrist circumference. Weight was monitored throughout the study. The
procedures for obtaining these anthropometric measurements were derived from the
NHANES III survey (Kuczmarski, 1994).
All body weights were measured USIng a medical scale (Health-O-Meter,
Continental Scale Corp., Chicago, IL) and subjects were dressed in street clothes without
shoes. Height was measured using the same medical scale. Subjects stood with heels
together, heels and back of head touching the metal bar of the stadiometer.
BLOOD COLLECTION AND PROCESSING
Fasting blood samples were collected prior to initiation of treatment and after
three months. All blood samples were kept in ice until processing. After centrifugation at
1500x g for 15 minutes, serum and plasma were aliquoted into smaller volumes and
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stored at -80aC until analysis. At the end of the study, all salnples were tested
simultaneously, in duplicate.
SERUM ANALYSES
All lipid parameters, excluding LDL-cholesterol, were measured using a Cobas-
Fara II Clinical Analyzer (Monclair, NJ). The machine was calibrated using Roche
Calibrator or HDL Direct Calibrator (Roche Diagnostic Systems; Somerville, NJ) before
each test. BioRad QCS Levelland Level 2 (Irvine, CA) were used as controls in all test
except for apo A and apo B when Roche Apolipoprotein Standard was used.
The reagent used for measuring total cholesterol concentrations in serum contains
cholesterol esterase, which releases cholesterol from its esters, and cholesterol oxidase,
which oxidizes the free cholesterol to produce hydrogen peroxide. A quinoneimine
complex is produced when hydrogen peroxide is combined with 4-aminoantipyrine and
phenol, which is measured photometrically at 500 l1ill.
Serum triglyceride levels were measured using a Roche reagent also. The
triglyceride reagent works similarly to the cholesterol reagent in that triglycerides are
converted to produce hydrogen peroxide through a series of enzymatic reactions and the
hydrogen peroxide reacts with 4-chlorophenol and 4-quinoneimine to form a
quinoneimine complex that can be read at 490-550 l1ill.
High-density lipoprotein content of the serum samples was determined by a direct
method (Ultimate HDL Direct; Roche Diagnostic Systems). Compounds in the reagents
solubilize cholesterol from lipid fractions other than HDL. The cholesterol in HDL is
then determined enzymatically.
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The Roche reagent for apo A-I contains antiserum which fonns a precipitate with
apo A-I in serum samples and the turbidity is measured at 340 llill. The apo B reagent
follows the same principle. Roche Apolipoprotein standard was used for both tests.
Antibody Reagent Set II for CRP (DiaSorin; Stillwater, MN) was used to
detennine serum levels of CRP. Again the Cobas-Fara was utilized. Antiserum is added
to the serum sample and antigen-antibody complexes form. After an incubation period,
absorbance is measured and CRP concentration is interpolated from a standard curve.
Low-density lipoprotein cholesterol was calculated using the Friedewald
equation: (Friedewald et aI., 1972)
LDL == eTC) - (HDL) - (TG/5)
DATA MANAGEMENT AND STATISTICAL ANALYSIS
Upon completion of the study, a trained graduate student entered data obtained
from the questionnaires into spreadsheets. As serum analyses were completed, results
were entered into a spreadsheet. All data obtained on subjects were held in a lock cabinet
with limited accessibility.
The experiment was a completely randomized design with repeated measures.
Treatment is the main plot factor and was applied to the subject, while baseline and final
were the repeated measures factor. Data were analyzed with PC SAS Version 8.1 (SAS
Inst., Cary, NC) using PROC MIXED. The simple effects of each factor with the other
factor held constant were examined with a SLICE option in an LSMEANS statement.
Significant differences were determined using alpha level == 0.05.
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CHAPTER IV
RESULTS
SUBJECT PARTICIPATION
Out of the 58 participants recruited, there was a 37% attrition. There were 20
women who completed the flaxseed regimen and 16 who completed the wheat regimen.
Nine women dropped out complaining of gastrointestinal discomfort. Another nine
participants dropped out because they felt that the study food was unpalatable. One
subject had time constraints and was unable to meet with study personnel. One subject
resumed menstruation while on the study and had to be excluded and another dropped out
for personal reasons. Subjects complaining of gastrointestinal problems and
unpalatability of study foods were given suggestions for incorporating the study food into
their diet to reduce these problems but they decided to end their participation in the study.
Of those in the flaxseed group completing the study, there was an 80% compliance with
the flaxseed supplement. There was an 87% compliance with the wheat supplement for
the wheat group.
NUTRIENT INTAKE
The average daily nutrient intake, as determined using seven-day food frequency
questionnaires, was similar in both groups (Table 2). This report does not include the
flaxseed or wheat supplement.
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ANTHROPOMETRIC MEASUREMENTS
The results of the anthropometric measurements are recorded in Table 3. There
were no significant differences in the baseline and final values of body weight and body
mass index (BMI) among the subjects in either treatment group. There was a significant
increase in the mean waist circumference measurement in the women in the wheat
treatment group (P==O.009). Hip circumference tended to increase in the wheat group
(P=O.072), while there was no change in the flaxseed group. There was a significant
increase in the waist to hip ratio in the flaxseed group (P=O.025) following treatment. The
ratio also increased in the wheat group but not significantly (P==O.079). The calculated
percent body fat decreased in both treatment groups but significance was only reached in
the flaxseed group.
SERUM ANALYSES
There was a significant decrease in the mean TC level following the flaxseed
treatment (P=O.007), as seen in Table 4, while there was no change following the wheat
treatment. After three months of the flaxseed regimen, the mean LDL-cholesterol
concentration decreased by 4.7% and the mean TG level decreased by 12.8%, however,
neither of these values was statistically significant. The mean HDL-cholesterol
concentration was also reduced slightly by the flaxseed regimen (P=O.091). Apo A and
apo B levels were reduced significantly by the flaxseed regimen but were not affected by
the wheat regimen. The mean CRP levels did not change after either treatment regimen
(Table 5).
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Flaxseed had no estrogenic effect as assessed by serum levels of estradiol
(P==O.90) (Table 5).
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CHAPTER V
DISCUSSION
We have shown that consumption of whole ground flaxseed can lower total
cholesterol in postmenopausal women. These findings are consistent with other clinical
studies, using similar amounts of flaxseed, conducted by Jenkins et al. (1999),
Bierenbaum et al. (1993), Cunnane et al. (1993;1995), and Arjmandi et al. (1998). In our
current study, LDL-cholesterol concentrations decreased by 4.7 % (P==0.218), which is
less than the 7.6% reduction seen by Jenkins et al. (1999) and the 14.7% reduction
reported by Arjmandi et al. (1998). Both Jenkins (1999) and Arjmandi (1998) used
flaxseed incorporated into bread and/or muffins, while whole ground raw flaxseed was
used in the current study. This may have contributed to this difference. It is unknown
whether the cholesterol-lowering compounds, such as the lignans and a-linolenic acid, in
flaxseed are equally as effective in raw and processed fOnTIs.
As with Jenkins et al. (1999), we observed that flaxseed reduced serum levels of
both apo Band apo A-I. Apo B is positively associated with heart disease. Elevated
levels of apo B are seen in CHD patients with or without elevated LDL-cholesterollevels
(Douste-Blazy & Kloer, 1989). It is a structural component in atherogenic particles such
as VLDL and LDL. Due to its function as a LDL receptor ligand, apo B aids in the
delivery of cholesterol to the tissues (Brown & Goldstein, 1986). Apo B particles have
been identified, along with LDL particles, in arterial plaque (Hoff et al. 1979). In the
current study, apo B was reduced by 10% (P==0.002), a change that could reduce the risk
of developing atherosclerosis and CHD.
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Apo A is the major apolipoprotein associated with HDL particles and its serum
level correlates with HDL-cholesterol levels (Shepherd & Packard, 1989). Apo A is also
found, to a lesser extent, in VLDL and chylomicrons. One source of HDL particles is the
remnants of VLDL and chylolnicrons (Shepherd et aI., 1989). On HDL particles, apo A
functions as a catalyst for lecithin:cholesterol acytransferase (LCAT), an enzyme
responsible for the reverse transport of cholesterol from peripheral tissues to the HDL
particles (Glomset, 1968). Flaxseed consumption reduced serum apo A concentration by
6% (P==O.003) however, it remained within normal limits for the study group (1.15-2.20
giL; Roche Apo A product insert). This decrease in apo A was to be expected with the
slight (P==O.09) decrease in HDL-cholesteroI.
It is unclear what component in flaxseed is responsible for its hypolipidemic
effect or whether it is a combination of components. Prasad (1999) demonstrated that
SDG, isolated from flaxseed, reduced atherosclerotic plaque as well as lowering serum
TC and LDL-cholesterol concentrations in rabbits. Also, omega-3 fatty acids have been
shown to reduce TC and TG (Simopoulos et aI., 1991). An additional possible
hypolipidemic component of flaxseed is fiber. Fiber has repeatedly been shown to lower
serum cholesterol levels (Fernandez, 2001; Saltzman et aI., 2001). Because these separate
components of flaxseed have hypolipidemic properties, it would be interesting to
determine which of these compounds is exerting the cholesterol-lowering effect seen in
this study or if these components work synergistically in flaxseed to produce this benefit.
An effective dose still remains to be determined as well as a comparison of the
effectiveness of raw and processed flaxseed.
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Flaxseed supplementation had no effect on serum levels of c-reactive protein.
Two possible explanations for this lack of effect are; 1) the serum levels of c-reactive
protein were not elevated at baseline in these subjects and 2) that flaxseed may not have a
measurable anti-inflammatory effect in humans.
In summary, the results of the present study reveal that reasonable dietary
changes, such as incorporating 40 g of flaxseed into the diet, are effective in lowering TC
and apo B levels in postmenopausal women. These effects were seen without altering
serum estradiol levels.
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Table 1
Composition of flaxseed and wheat-based control regimen
Measures Flaxseed Weat
Per 40g Per40g
Energy, kcal 237.0 202.3
Fat,g 12.6 8.9
Fiber, g 2.1 2.0
Protein, g 8.6 10.6
Mineral, g 1.5 1.3
Calcium, mg 133 14
Phosphorous, mg 0.9 1.1
Gross energy analyzed by bomb calorimetry (Parr 1261 Calorimeter, Parr lnst. Co.,
Moline, IL), crude protein by the AOAC Kjeldahl method (AOAC, 1984), fat by ether
extraction (AOAC,1984), calcium content by atomic absorption spectrophotometer
(Perkin Elmer Atomic Absorption Spectrophotometer, model 5100PC, Perkin Elmer,
Norwalk, CT) (Hill et aI., 1986) and phosphorus was measured using a kit from Roche
Diagnostic (Branchburg, NJ).
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Table 2
Daily nutrient intake as determined from 7-day food frequency questionnaires.
(Values do not include treatlnent regimen and calcium plus vitamin D supplement)
Daily intake Flaxseed Wheat
Baseline Final
p
Baseline Final
p
value value
Total energy, 1619±137 1529 ± 140 0.55 1786±140 1531 ± 154 0.13(kcal)
Nutrients (g)
Protein 64 ± 6 65 ± 6 1.00 74± 6 60± 7 0.06
Carbohydrates 223 ±22 208 ± 22 0.58 235 ± 22 205 ± 25 0.33
Dietary fiber 22 ± 2 18 ± 2 0.13 19 ± 2 17 ± 3 0.31
Total fat 56 ± 6 59 ± 6 0.69 64 ± 6 53 ± 6 0.17
Saturated fat 20 ± 3 19 ± 3 0.73 23 ± 3 20 ± 3 0.37
Polyunsaturated 10 ± 1 12 ± 1 0.12 12 ± 1 9±1 0.07Fat
Minerals (mg)
Calcium 718 ± 111 745 ± 112 0.77 838±113 740 ± 121 0.34
Magnesium 270 ±26 255 ± 26 0.66 294 ± 26 260 ± 29 0.34
Phosphorus 1038±115 1009 ± 116 0.77 1199±118 954 ± 126 0.03
Values are mean ± SE; n== 20 for flaxseed regimen and 16 for wheat regimen.
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Table 3
Subject characteristic
Measures Flaxseed Wheat(n=20) (n=16)
Baseline Final
p
Baseline Final
p
value value
Age (years) 54 ± 8 55 ± 5
Time since
menopause 11 ±1.57 6.44 ±1.67
(years)
Weight (kg) 78.2 ± 4.3 77.9 ± 4.3 0.650 74.2 ± 4.8 75.1 ±4.8 0.092
Body Mass 29.1 ± 1.6 29.0± 1.6 0.648 28.7±1.8 29.1±1.8 0.072Index, (kg/m2)
Waist
circumference 95.9 ± 3.7 97.9 ± 3.7 0.280 96.4 ± 4.1 101.9±4.1 0.009
(em)
Hip
circumference 112.1 ±3.5 110.6 ± 3.5 0.134 109.8 ± 3.9 111.9 ± 3.9 0.072
(em)
Waist to Hip 0.86 ± 0.02 0.90 ± 0.02 0.025 0.88 ± 0.02 0.91 ± 0.02 0.079Ratio
Body Fat, % 31.3 ± 2.2 29.2 ± 2.2 0.033 38.2 ± 2.3 36.8 ± 2.3 0.172
Values are mean ± SE.
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Table 4
Effects of three-month flaxseed supplementation on serum lipid parameters in postmenopausal women
Flaxseed Wheat
p % Change p % Change
Baseline Final
value from Baseline Final value frombaseline baseline
Lipids
Total
cholesterol 5.76 ± 0.25 5.44 ± 0.25 0.01 -5.5 5.95 ± 0.28 6.13 ± 0.28 0.18 +3
(mmollL)
l;.)
~
LDL-
cholesterol 3.21 ± 0.25 3.06 ± 0.25 0.22 -4.7 3.52 ± 0.28 3.64 ± 0.28 0.37 +3.4
(mmollL)
HDL-
cholesterol 1.89 ± 0.09 1.80 ± 0.09 0.09 -4.5 1.61±0.10 1.67 ± 0.10 0.34 +3.7
(mrn.ol/L)
Triglycerides 1.48 ± 0.16 1.29±0.16 0.14 -12.8 1.56±0.19 1.74 ± 0.19 0.20 +11.5(mmol/L)
Apo A-I (giL) 1.98 ± 0.05 1.86 ± 0.05 0.003 -6 1.94 ± 0.06 1.95 ± 0.06 0.82 +0.5
Apo B (giL) 1.34 ± 0.07 1.24 ± 0.07 0.002 -7.4 1.38 ± 0.08 1.44 ± 0.08 0.07 +4.3
Values are mean ± SE; n== 20 for flaxseed regimen and 16 for wheat regimen.
Table 5
Effects of three-month flaxseed supplementation on serum 17p-estradiol (E2) and C-
reactive protein concentrations in postmenopausal women
Flaxseed Wheat
Baseline Final
p
Baseline Final
p
value value
Hormone
E2 (pmol/L) 34.1 ±7.4 33.0 ±7.4 0.90 28.8 ±8.4 20.0 ±8.4 0.36
Inflammation
C-reactive
protein 7.62 ± 2 5.47 ± 2 0.31 11.36 ±_2.56 13.54 ± 2.56 0.42
(mg/L)
Values are mean ± SE; n== 20 for flaxseed regimen and 16 for wheat regimen.
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